Recombinant Mycobacterium tuberculosis fusion protein (EC) | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Medicine type: Biologic
Therapeutic area: Prevention & diagnosis
Indications recorded in the public source: Diagnosis of Mycobacterium tuberculosis infection. Recommended for infants and children aged 6 months or older and adults under 65 years of age. The skin-test result is not affected by BCG vaccination, and the product can assist the clinical diagnosis of tuberculosis.
Indication source and scope: Source date(s): 2024, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
Prescribing-information limitations: A verifiable complete prescribing-information document has not yet been obtained. Available approval records or NHSA submissions support the indications shown; the latest full scope needs confirmation.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: No additional restriction is specified for this formulary entry. General formulary rules and legally approved indications still apply.
Insurance period: 2025-01-01 to 2026-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions